GRN Gesundheitszentren Rhein-Neckar gGmbH
- Address
- Roentgenstrasse 1, 69469 Weinheim, Germany
GRN Gesundheitszentren Rhein-Neckar gGmbH
GRN Gesundheitszentren Rhein-Neckar gGmbH is a comprehensive medical research center with expertise in oncology and vascular interventional medicine. The institution demonstrates particular strength in investigating innovative treatment strategies for breast cancer and peripheral vascular disease, contributing to advancing personalized medicine approaches.
- HER2-positive and hormone receptor-positive breast cancer with targeted therapy combinations
- Intermediate-risk early breast cancer with novel endocrine and CDK4/6 inhibitor strategies
- Peripheral arterial disease interventions with contrast-sparing techniques for kidney protection
In oncology research, the center focuses on precision medicine approaches for breast cancer, particularly investigating neoadjuvant therapies that combine endocrine treatment with targeted agents such as PI3K inhibitors and CDK4/6 inhibitors. The research emphasizes biomarker-driven therapy selection, including PIK3CA mutation status and hormone receptor profiles. Additionally, the center conducts groundbreaking work in vascular medicine, exploring contrast-associated acute kidney injury prevention through automated Carbon Dioxide injection techniques during peripheral vascular interventions, demonstrating commitment to improving patient safety outcomes in high-risk populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 20 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1AstraZeneca AB2active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in GRN Gesundheitszentren Rhein-Neckar gGmbH
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer - GeparPiPPa | GBG Forschungs GmbH | Phase II | Recruiting | Dec 2022 | — |
IMP list
lock Showing 1 of 20 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anastrozole | 1 | Unknown | 2024-02-23 | 2024-02-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.